Sarah Sammons, MD, medical oncologist, clinical investigator in the Breast Oncology Center, associate director of the ...

Patients with HER2-positive advanced or metastatic breast cancer received trastuzumab deruxtecan every 3 weeks.

Enhertu locks onto HER2 receptors – which are found in some breast cancer cells – and can stop them from growing (Daiichi Sankyo, AstraZeneca via AP) Exhausted, with tumours growing in her ...

Enhertu (fam-trastuzumab deruxtecan-nxki*) is a prescription drug used to treat certain kinds of cancer, including breast cancer. Enhertu is given by intravenous infusion (an injection into a vein ...

China’s Duality Biotherapeutics has filed (PDF) paperwork for a Hong Kong IPO, seeking an undisclosed sum to power a broad pipeline of antibody-drug conjugates toward approval. The filing ...

Enhertu (fam-trastuzumab deruxtecan-nxki) is a prescription drug that’s used to treat certain cancers, such as breast cancer. Enhertu can cause side effects that range from mild to serious ...

Daiichi Sankyo and AstraZeneca's ENHERTU has received breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) for the treatment of a specific type of metastatic ...

(IN BRIEF) AstraZeneca and Daiichi Sankyo’s Enhertu has received conditional approval in China for treating locally advanced or metastatic HER2-positive gastric cancer, following promising results ...

New changes to the UK's immigration laws, including substantial increases to visa fees and higher salary thresholds for applicants, are raising concern among cancer researchers and other stakeholders ...

The FDA has approved the use of AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu for all HER2-positive solid tumours, in a first for both HER2 inhibitors and ADCs. Enhertu ...

In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every ...

The results for Enhertu in HER2-low breast cancer were released at the plenary session of the American Society of Clinical Oncology and delivered "data fit for a queen", analysts Luisa Hector ...